This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Champions Oncology Stock (NASDAQ:CSBR) 30 days 90 days 365 days Advanced Chart Get Champions Oncology alerts:Sign Up Key Stats Today's Range$9.00▼$9.7250-Day Range$9.11▼$10.9652-Week Range$3.60▼$11.99Volume32,633 shsAverage Volume18,414 shsMarket Capitalization$94.81 millionP/E Ratio21.38Dividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. Read More Champions Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreCSBR MarketRank™: Champions Oncology scored higher than 79% of companies evaluated by MarketBeat, and ranked 232nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChampions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialChampions Oncology has a consensus price target of $12.00, representing about 74.4% upside from its current price of $6.88.Amount of Analyst CoverageChampions Oncology has received no research coverage in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is 21.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 277.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is 21.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.15.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 25.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.55% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 10.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.08 Percentage of Shares Shorted1.55% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 10.31%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSBR Stock News HeadlinesChampions Oncology Reports Record Revenue and ProfitabilityJuly 28, 2025 | msn.comChampions Oncology Inc (CSBR) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...July 24, 2025 | finance.yahoo.comWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."September 6 at 2:00 AM | Altimetry (Ad)T20 Champions League set to return after ICC green light, first match could be in September 2026: ReportJuly 20, 2025 | msn.comChampions League T20 set to be relaunched; ICC mulls two-tier Test structureJuly 20, 2025 | msn.comChampions League T20 set for dramatic 2026 return but ICC could deliver crushing blow to Test cricket's future: ReportJuly 20, 2025 | msn.comA T20 Champions League is coming, and so is crunch time for Test cricketJuly 20, 2025 | msn.comEngland Champions vs Pakistan Champions LIVE, WCL: England Start Chase Of 161 vs PakistanJuly 18, 2025 | msn.comSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) issued its earnings results on Wednesday, July, 23rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter. The biotechnology company earned $12.35 million during the quarter. Champions Oncology had a trailing twelve-month return on equity of 196.12% and a net margin of 8.26%. Read the conference call transcript. Who are Champions Oncology's major shareholders? Top institutional investors of Champions Oncology include Jane Street Group LLC (0.13%) and XTX Topco Ltd (0.10%). Insiders that own company stock include Ronnie Morris and Daniel Newman Mendelson. View institutional ownership trends. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings7/23/2025Today9/06/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:CSBR CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year Founded2007Price Target and Rating Average Price Target for Champions Oncology$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+74.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E Ratio21.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.70 million Net Margins8.26% Pretax Margin8.12% Return on Equity196.12% Return on Assets16.62% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual Sales$56.94 million Price / Sales1.67 Cash Flow$0.46 per share Price / Cash Flow15.08 Book Value$0.27 per share Price / Book25.48Miscellaneous Outstanding Shares13,780,000Free Float7,305,000Market Cap$94.81 million OptionableOptionable Beta0.51 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CSBR) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
